



Pixium Vision strengthens its intellectual property in Europe and the US

- **Patent maintained in Europe following opposition claim by a competitor**
- **Patent granted in the US**

Paris, 13 April 2015 – 07h30 Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announced the strengthening of its patent protection on IRIS[®], its first Vision Restoration System (VRS), following recent decisions of the European and US patent Offices.

Khalid Ishaque, CEO of Pixium Vision, declared *«The similar decisions made both by the European and US Patent Offices not only highlight the uniqueness of the technical solutions proposed by Pixium Vision but also the quality of our multidisciplinary teams. More generally, the common position of European and US patent Offices reflects the maturity and strength of the company's patent portfolio.»*

Following an opposition filed by a direct US competitor against the patent EP1986733 with claims covering flexible multilayered electrode array favoring contact and electrical stimulation of the inner retina cells, the European Patent Office concluded that the maintained patent met the requirements of the European Patent Convention (EPC).

Additionally, the US Patent Office granted Pixium Vision the corresponding US patent on this flexible multilayered electrode array (US 8,918,186).

This complements other decisions recently issued by the European and US Patent Offices notably including the electrical circuit controlling voltage or charge in IRIS[®] (issued European patent-EP1827591- and allowance of equivalent US patent), localization of the return electrode (issued European patent EP1915115), power supply system of IRIS[®] (allowance of the US patent equivalent to already issued European patent EP2259843) or the electronic configuration of IRIS[®] (issued European -EP2229212- and US -US 9,002,463- patents).

Pixium Vision currently holds 28 patent families, with more than 250 patents and patent applications registered. It has also obtained licences for 7 patent families held by third parties.

Contacts

Pixium Vision

Pierre Kemula, CFO
contact@pixium-vision.com
+33 1 76 21 47 30

Investor Relations

Citigate Dewe Rogerson
Lucie Larguier – Laurence Bault (Paris)
pixium-vision@citigate.fr
+33 1 53 32 84 78

About Pixium Vision (www.pixium-vision.com, @PixiumVision)

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. Pixium Vision's VRS are composed of various high-tech elements, associated with a surgical intervention as well as a rehabilitation period. These systems aim to ultimately provide blind patients with vision approaching that of a normal healthy eye.

Clinical trials are currently underway with the VRS IRIS[®] in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. The results of these studies will be used to apply for CE mark. The approval of IRIS[®] is expected in 2015.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.



Pixium Vision is listed on Euronext (Compartment C) in Paris.

ISIN: FR0011950641 ; Mnemo: PIX

IRIS[®] is a trademark of Pixium-Vision SA

Disclaimer

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Documents de Base filed with the AMF under number I. 14-030 on May 12, 2014 and Chapter 2 "Risk Factors related to the Offer" in the prospectus, which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).